Sanofi SA (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 213   

Articles published

SNY 49.47 -0.31 (-0.62%)
price chart
Amgen, Inc. Or Sanofi SA (ADR) - Who Will Rule The Cholesterol Market?
Amgen, Inc. (NYSE:AMGN) and Sanofi SA ADR (NYSE:SNY) are all set to change the cholesterol drug market with their powerful new treatments that belong to a new class of drugs called PCSK9 protein inhibitors.
GlaxoSmithKline plc (ADR), Merck & Co., Inc., Pfizer Inc., Sanofi SA (ADR ...
Home > GlaxoSmithKline plc (ADR), Merck & Co., Inc., Pfizer Inc., Sanofi SA (ADR): Are Big Pharma Stocks In Trouble?
Novo Nordisk A/S, Sanofi SA, Merck & Co Top $62 Billion Diabetes Market In ...
According to a report compiled by data analytics firm GlobalData, the 10 leading diabetes drug-makers generated around $62 billion in 2014 global sales, up 5.1% year-over-year (YoY).
Sanofi SA-Regeneron Pharmaceuticals Cholesterol Drug Well Tolerated But ...
Sanofi SA (ADR) (NYSE:SNY), which jointly developed cholesterol-lowering drug Praluent with Regeneron Pharmaceuticals Inc (NASDAQ:REGN), received a setback Friday when the US Food and Drug Administration (FDA) said that while the drug ...
FDA Panel Clears Product Path For Sanofi, Regeneron Pharmaceuticals  Yahoo News
Sanofi SA (ADR) Chief Strategy Officer Resigns; Company Facing Another ...
Sanofi SA (ADR) (NYSE:SNY), the French pharmaceutical giant, is facing another turmoil as its chief strategy officer, David-Alexandre Gros, has resigned only six months after the company's famous chief executive officer, Chris Viehbacher, was ousted by ...
Dyax Corp. (DYAX) Takeover Talk: Shire PLC (ADR), Sanofi SA (ADR) Among ...
Dyax Corp. (NASDAQ:DYAX) was flagged as an attractive acquisition target by Bloomberg on Wednesday, on the back of its investigational drug that reported promising Phase 1b data at the annual meeting of the European Academy of Allergy and Clinical ...
GlaxoSmithKline plc (ADR) (GSK), Novartis AG (ADR) (NVS), Sanofi SA (ADR ...
The stocks include London-based GlaxoSmithKline plc (ADR) (NYSE:GSK), Switzerland-based Novartis AG (ADR) (NYSE:NVS) and France-based Sanofi SA (ADR) (NYSE:SNY). The veteran portfolio manager has an impressive track-record of managing to ...
GlaxoSmithKline Plc (ADR) (NYSE:GSK) Unveils Big Business Growth Targets  WallStreetPR (blog)
Driven By Amgen, Inc. And Sanofi SA (ADR), US Drug Price War May Shift From ...
As per research presented at the annual meeting of the American College of Cardiology in March and conducted separately by Amgen, Inc. (NASDAQ:AMGN), and Sanofi SA (ADR) (NYSE:SNY) along with its development partner Regeneron Pharmaceuticals ...
Sanofi SA (ADR) May Launch Toujeo In The US On Monday
Sanofi SA ADR (NYSE:SNY) plans to launch its new insulin, Toujeo, for the treatment of diabetic patients in the US as early as this Monday, people familiar with the matter said.
Sanofi SA (ADR) Decides Against Discounting Toujeo More Than Lantus
Sanofi SA (ADR) (NYSE:SNY) has declared it will not offer steeper rebates for its newly approved insulin product Toujeo than those already existing on its older blockbuster version Lantus, soon to go off-patent in the US and EU.